Steve Bryson, PhD,  science writer—

Tyvaso (inhaled treprostinil) significantly improved the exercise capacity of people with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD), achieving its primary endpoint in the…

Newborns were seen to be at an increased risk of pulmonary hypertension (PH) if they developed poorly while in the womb and had meconium aspiration syndrome, meaning they inhaled their feces during birth, a study from Pakistan reported.  The…

People with pulmonary arterial hypertension (PAH) who were treated with Uptravi (selexipag) had a lower risk and rate of hospitalization than those taking Orenitram (treprostinil), a real-world analysis revealed. The study,…

Newly published research has detailed the underlying biochemical process behind Acceleron Pharma’s investigational therapy sotatercept (ACE-011) for the potential treatment of people with pulmonary arterial hypertension (PAH). The findings, in two rat models of PAH,…

Newly identified mutations that contribute to a higher susceptibility of idiopathic pulmonary arterial hypertension (IPAH) in people from China, were found in a pathway commonly targeted by therapies that dilate blood vessels (vasodilators), a new study reports.  The authors suggested that screening for these mutations…

Genetic screening of patients with persistent pulmonary hypertension of the newborn (PPHN) found three rare mutations associated with the condition, suggesting it has a genetic basis, a study reports. The researchers also found that a link between PPHN and genetic variants…

Orenitram (treprostinil tablets) reduced clinical worsening and slowed disease progression in people with pulmonary arterial hypertension (PAH) who had recently begun treatment with an alternative approved therapy, a Phase 3 clinical trial has found. Trial findings were reported in the study, “Combination Therapy with Oral Treprostinil for Pulmonary…

Infants with mild or severe forms of persistent pulmonary hypertension of the newborn, who were discharged from hospital, were significantly more likely to be readmitted or die within their first year of life, with the primary cause being congenital abnormalities, a study has…

Analysis of a North American pediatric registry revealed significant variability of pulmonary hypertension (PH) subtypes among children of different racial and ethnic groups, with reduced survival rates among black children with lung disease-associated PH, a new study reports. The study, “Racial…

V-Wave’s new interatrial shunt — a medical device designed to reduce arterial heart pressure — has been granted breakthrough device designation by the U.S. Food and Drug Administration (FDA) for the treatment of people…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to sotatercept for the treatment of pulmonary arterial hypertension (PAH), according to…

Only two non-invasive diagnostic tests are required to best predict the risk of adverse events in people with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH), a new study suggests. The study, “Guideline implementation and early risk assessment in pulmonary…